In this context, rapamycin interacts with FKBP5/FKBP51 (and FKBP1A/FKBP12, see below under Parkinson’s disease), inhibiting the mTORC1 complex and increasing cellular clearance mechanisms. Here, FKBP1A is linked to Parkinson disease.